Table 1 Baseline characteristics of the patients with eGFR > 60 and < 30 ml/min/1.73 m2.

From: The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function

 

eGFR < 30 ml/min/1.73 m2

eGFR > 60 ml/min/1.73 m2

p-value

Mean eGFR (ml/min/1.73 m2)a

25.1 ± 3.4

65.6 ± 4.6

 < 0.0001

Age (years)a

68 ± 6

64 ± 9

0.2

Sex (F-female, M-male)

F 29.4% (n = 5)

M 70.6% (n = 12)

F 64.7% (n = 11)

M 35.3% (n = 6)

0.04

BMI (kg/m2)a

32.1 ± 3.9

31.3 ± 6

0.05

Duration of diabetes (years)a

16 ± 5

10 ± 4

0.001

Insulin therapy (%)

88.2% (n = 15)

29.4% (n = 5)

0.0005

HbA1c (%)b

7.3 (5.9–9.7)

6.8 (5.8–8.2)

0.005

Ischemic heart disease (%)

94.1% (n = 16)

64.7% (n = 11)

0.03

History of cardiovascular events (%)

47% (n = 8)

5.9% (n = 1)

0.02

History of smoking (%)

58.8% (n = 10)

17.7% (n = 3)

0.01

Duration of hypertension (years)b

16 (10–20)

10 (8–15)

0.01

The number of antihypertensive drugsc

4 (3–6)

4 (3–5)

0.01

ACE inhibitor

21.4% (5/17)

41.1% (7/17)

0.47

Angiotensin II receptor blocker

35.3% (6/17)

52.9% (9/17)

0.3

Spironolactone

0% (0/17)

5.9% (1/17)

0.3

Diuretics

100% (17/17)

88.2% (15/17)

0.14

Centrally-acting antihypertensives

17.7% (3/17)

23.5% (4/17)

0.67

Baseline SBP (mmHg)a

143 ± 14

132 ± 14

0.04

Baseline DBP (mmHg)a

75 ± 7

74 ± 8

0.74

  1. BMI, body mass index; HbA1c, glycated hemoglobin; ACE, angiotensin converting enzyme; SBP, systolic blood pressure; DBP, diastolic blood pressure.
  2. aMean ± standard deviation.
  3. bMedian with interquartile range (IQR).
  4. cMedian with (min.-max) range.
Back to article page